Mounjaro (tirzepatide) is a once-weekly injection that produces significant weight loss, with clinical trial participants losing 15% to 21% of their body weight over 72 weeks depending on the dose. It works by activating two hormone pathways in your body that reduce appetite, improve how your body handles fat, and slow digestion so you feel full longer. Here’s what the process of taking it actually looks like.
Mounjaro vs. Zepbound: Which One Is for Weight Loss?
This is an important distinction. Mounjaro and Zepbound contain the exact same active ingredient, tirzepatide, but the FDA approved them for different purposes. Mounjaro is approved for type 2 diabetes. Zepbound is the version approved specifically for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition like high blood pressure or high cholesterol.
Some doctors prescribe Mounjaro off-label for weight loss, especially when Zepbound has availability issues. The medication inside the pen is identical. But if your primary goal is weight loss and you don’t have type 2 diabetes, Zepbound is the FDA-approved option, and that distinction can matter for insurance coverage.
How the Dose Escalation Works
Tirzepatide follows a slow, structured ramp-up schedule designed to let your body adjust gradually. You don’t start at a therapeutic dose. Instead, you begin at 2.5 mg once per week, which is purely an introductory dose. It’s not expected to produce major results on its own. After four weeks at 2.5 mg, you move up to 5 mg.
From there, your prescriber can increase the dose by 2.5 mg increments every four weeks or longer. The available doses are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The maximum is 15 mg once weekly. Not everyone needs the highest dose. Your prescriber will adjust based on how you’re responding and how well you tolerate each step.
This gradual escalation isn’t optional. Jumping to a higher dose too quickly is the fastest way to trigger severe nausea, vomiting, and other digestive side effects. The schedule exists specifically to reduce that risk.
What the Weight Loss Numbers Look Like
The landmark SURMOUNT-1 trial tested tirzepatide in adults with obesity or overweight (without diabetes) over 72 weeks. The results by dose were striking:
- 5 mg: 15% average body weight loss
- 10 mg: 19.5% average body weight loss
- 15 mg: 20.9% average body weight loss
For someone starting at 250 pounds, a 20% loss means roughly 50 pounds over about a year and a half. These are averages, so individual results vary. Some people lose more, some less. Most of the weight loss happens during the first several months as doses increase, then gradually plateaus.
How to Inject It
Tirzepatide comes in a prefilled, single-dose pen. You inject it once a week, on the same day each week, at any time of day, with or without food. You can inject into your stomach (at least two inches from your belly button), the front of your thigh, or the back of your upper arm. Rotate your injection site each week to avoid skin irritation.
If you miss a dose and fewer than four days have passed since your scheduled day, take it as soon as you remember. If more than four days have passed, skip that dose and take your next one on the regular day. You can change your injection day if needed, as long as at least three days have passed since your last dose.
Managing Side Effects
The most common side effects are digestive: nausea, vomiting, diarrhea, constipation, and general stomach upset. These tend to be worst during the first few weeks at each new dose level and improve as your body adjusts. The drug’s design actually helps here. Tirzepatide leans more heavily on one of its two hormone pathways (the GIP pathway), which is less associated with nausea than the GLP-1 pathway that older medications rely on exclusively.
Still, what you eat makes a real difference in how you feel. During dose increases especially, avoid greasy, fatty, very sweet, or spicy foods. Cut back on caffeine and alcohol. If you’re experiencing diarrhea, reduce high-fiber foods temporarily. Eating smaller meals throughout the day instead of large ones can also help, since the medication already slows how quickly your stomach empties.
Skipping meals or eating too little can actually make nausea and constipation worse. Your appetite will naturally decrease on this medication, sometimes dramatically. But you still need adequate nutrition. Lean proteins, vegetables, whole grains, and staying well hydrated will support both your weight loss and your comfort level.
How to Store the Pen
Keep unused pens in the refrigerator between 2°C and 8°C (roughly 36°F to 46°F). If you need to, you can store an unused pen at room temperature (up to 30°C or 86°F) for up to 30 days. Once you’ve used a pen, store it at room temperature and discard it after 30 days, even if medication remains inside. Never freeze the pens, and keep them out of direct sunlight or extreme heat.
Why Diet and Exercise Still Matter
Tirzepatide is approved as an addition to a reduced-calorie diet and increased physical activity, not a replacement for them. The clinical trials that produced those 15% to 21% weight loss results included lifestyle modifications as part of the protocol. The medication suppresses your appetite and changes how your body processes food and fat, but exercise preserves muscle mass during weight loss and improves cardiovascular health in ways the drug alone doesn’t address.
Because your appetite drops significantly, you may find it easy to undereat. This can lead to muscle loss, nutrient deficiencies, and fatigue. Prioritizing protein at every meal helps protect lean muscle. Many prescribers recommend aiming for 60 to 100 grams of protein daily, though your specific target depends on your body size and activity level.
Who Should Not Take It
Tirzepatide carries a boxed warning (the FDA’s most serious label warning) related to thyroid tumors observed in animal studies. It is contraindicated if you or anyone in your family has a history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. You should not use Mounjaro and Zepbound together, or combine either with another GLP-1 receptor agonist.
If you develop a lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath while on the medication, those warrant prompt medical attention. Symptoms of pancreatitis, particularly severe abdominal pain that radiates to your back, also require immediate evaluation.